ACADIA Pharmaceuticals's total inventories for the quarter that ended in Mar. 2026 was €27.3 Mil. ACADIA Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €28.5 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. ACADIA Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €3.09.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
ACADIA Pharmaceuticals's Days Inventory for the
three
months ended in Mar. 2026 was 121.10.
Inventory Turnover measures how fast the company turns over its inventory within a year.
ACADIA Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.75.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ACADIA Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.12.
ACADIA Pharmaceuticals (FRA:DR6) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
ACADIA Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ACADIA Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
ACADIA Pharmaceuticals Total Inventories Related Terms
ACADIA Pharmaceuticals Total Inventories Historical Data
* Premium members only.
The historical data trend for ACADIA Pharmaceuticals's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
ACADIA Pharmaceuticals (FRA:DR6) has a Total Inventories of €27.3 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Total Inventories too high?
ACADIA Pharmaceuticals' current Total Inventories is €27.3 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Total Inventories compare to EWTX and CRNX?
ACADIA Pharmaceuticals' Total Inventories of €27.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Total Inventories is €27.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (FRA:DR6) is currently considered Fairly Valued. The stock's GF Value™ is €21.67, compared to a current price of €20.55 — trading 5.2% below its estimated fair value. The current Total Inventories is €27.3 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For ACADIA Pharmaceuticals (FRA:DR6), the current Total Inventories is €27.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (FRA:DR6) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued.
The current stock price of €20.55 is trading 5.2% below its estimated GF Value™ of €21.67.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for FRA:DR6:
Total Inventories: €27.3 Mil
GF Value™: €21.67 vs. price of €20.55 (5.2% below fair value)
No single metric tells the full story. See the FRA:DR6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
76GF Score
Get the complete analysis for FRA:DR6
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DR6 has been successfully added to your 
